Atypical cutaneous herpes virus infection associated with fludarabine chemotherapy of lymphoma.
Satzger
Imke
I
Kapp
Alexander
A
Gutzmer
Ralf
R
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D004279:DNA, Viral / Q000032:analysis; D003937:Diagnosis, Differential; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005145:Face; D005260:Female; D006564:Herpesviridae / Q000235:genetics; D006566:Herpesviridae Infections / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D019653:Myeloablative Agonists / Q000009:adverse effects; D009666:Nose; D012611:Scrotum; D017193:Skin Diseases, Viral / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004279:DNA, Viral; D004791:Enzyme Inhibitors; D019653:Myeloablative Agonists; D004248:DNA (Cytosine-5-)-Methyltransferases; D014740:Vidarabine; C024352:fludarabine